Heart failure Drug's hidden effects revealed in new study

NCT ID NCT04498780

Completed Knowledge-focused Sponsor: University of Leipzig Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the drug Sacubitril-Valsartan changes heart function in people with heart failure and reduced pumping ability. Researchers used a non-invasive method to measure heart pressure and volume in 117 participants. The goal is to uncover the mechanisms behind the drug's known benefits, such as fewer hospitalizations and better quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacubitril-Valsartan
What this could lead to: If successful, this could help doctors understand why Sacubitril-Valsartan improves symptoms and survival in heart failure patients.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION

Contacts and locations

Locations

Kardiopraxis Schirmer

Kaiserslautern, Germany
University of Leipzig

Leipzig, Saxony, 04103, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.